• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Dermatology Times 2023 In Review: Skin Cancer


As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.

The Immune Profile of Merkel Cell Carcinoma

New clues about the immune system response to MCC may be able to help guide future treatment strategies.

Say No to Nasal Tanning Sprays

Dermatologists have long warned tan seekers about the detrimental effects of ultraviolet exposure and tanning beds, strongly discouraging their use; nasal tanning sprays are no different.

Tirbanibulin Improves Skin in Patients with Actinic Keratosis

A poster presentation from SBS 2023 reviewed the clinician satisfaction of tirbanibulin for the treatment of actinic keratosis.

The Human Microbiota and Skin Cancer

Recent research highlighted the important role of the skin’s microbiota in maintaining the homeostasis of the skin and the potential role the human microbiota may play in the development of skin cancer.

Basal Cell Carcinoma Removed From President Biden’s Chest

The commander-in-chief’s cancerous tissue was successfully removed last month.

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

COVID-19's Impact on Treating Elderly Patients With Skin Cancer

Researchers said the pandemic played a role in healthcare providers’ ability to safely and promptly treat various skin cancers.

Interventions in Minimal Residual Disease Lead to Long-Term Melanoma Control

In a recent review, authors explored the effects of targeted therapies and immune checkpoint inhibitors on melanoma, particularly in minimal residual disease.

SLIDESHOW: Highlights from the 2023 American College of Mohs Surgery Meeting

Catch up on the innovative pearls shared at the 2023 American College of Mohs Surgery including strategies to enhace the patient experience, the role artificial intelligence plays in dermatologic care, and more.

Preparing Patients for the Summer Sun: Derms Debunk 5 Sunscreen Myths

Leading clinicians debunk 5 of the most common sunscreen myths.

New Long-Term KEYNOTE-716 Data Presented at ASCO 2023

Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward.

Managing aBCC and aCSCC With Cemiplimab: Tips From Matthew Reynolds, PA-C

Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.

Acral Lentiginous Melanoma More Common in Southeast Asian Patients Than Other Asian American & Pacific Islander Groups

A poster presentation from the 19th Annual Skin of Color Society Scientific Symposium analyzed the differences in presentation of cutaneous melanoma among Asian American and Pacific Islander patients.

Differentiating Merkel Cell Carcinoma in Skin of Color

The clinical presentations of Merkel cell carcinoma in patients with skin of color require dermatology providers to be more aware of the nuances in diagnosis and management.

Replimune and Incyte to Collaborate on Clinical Trial to Study RP1 in Combination With INCB99280 for CSCC

Both companies are hoping to make a positive impact in the neoadjuvant setting of cutaneous squamous cell carcinoma.

Recognizing and Managing Pediatric Skin Cancer With Early Detection and Education

Although rare, clinicians are encountering more pediatric patients who are at an increased risk of skin cancer due to immunosuppression.

World Trade Center 9/11 Rescue Workers Show Higher Risk of Melanoma

Rescue workers had a higher rate of malignant melanoma between 2005 and 2015 compared to the general population of New York State.

Aircrews Face Increased Risk of Developing Skin Cancer

Frequent fliers, including pilots and cabin crew, are exposed to greater levels of UV and cosmic ionizing radiation than the general population, leading to higher incidence of skin cancers.

FDA Approves Nivolumab for Completely Resected Stage IIB/C Melanoma

Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.

40-GEP Identifies Patients Who Benefit Most From Adjuvant Radiation Therapy With Improved Metastasis-Free Survival of cSCC

The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.

Mohs Surgery Improves Rates of Nodal Metastasis and Disease Specific Death in cSCC

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

ChatGPT Performs Well in Actinic Keratosis Pathogenesis and Risk Factor Knowledge, Lacks in Diagnosis and Treatment

ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.

Moderna and Merck’s V940 Plus Pembrolizumab Demonstrates Improvement in RFS and DMFS in Stage III/IV Melanoma After Complete Resection

At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.

Immunotherapy in Melanoma: Navigating Special Patient Populations

The Society for Immunotherapy of Cancer recently published insights into the management of patients with preexisting autoimmune disease, solid organ transplant recipients, elderly individuals, those living with HIV, pregnant patients, and those with rare noncutaneous subtypes of melanoma.

For all skin cancer news, click here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.